$50.31 Million in Sales Expected for Collegium Pharmaceutical Inc (COLL) This Quarter
Wall Street brokerages expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to post sales of $50.31 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $44.41 million to $56.20 million. Collegium Pharmaceutical reported sales of $2.17 million in the same quarter last year, which indicates a positive year over year growth rate of 2,218.4%. The company is expected to issue its next earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full year sales of $50.31 million for the current year, with estimates ranging from $251.06 million to $311.98 million. For the next fiscal year, analysts forecast that the firm will report sales of $352.53 million per share, with estimates ranging from $315.51 million to $374.47 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.02. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. The company had revenue of $10.79 million during the quarter, compared to the consensus estimate of $9.88 million. The business’s quarterly revenue was up 728.4% compared to the same quarter last year.
Collegium Pharmaceutical (NASDAQ COLL) traded down $2.41 on Thursday, hitting $26.80. The stock had a trading volume of 1,174,647 shares, compared to its average volume of 599,518. Collegium Pharmaceutical has a 12 month low of $7.37 and a 12 month high of $29.90. The firm has a market capitalization of $884.24, a P/E ratio of -10.72 and a beta of 0.81.
In related news, Chairman Michael Thomas Heffernan sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total value of $500,200.00. Following the completion of the transaction, the chairman now owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Alison B. Fleming sold 6,928 shares of the business’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total value of $132,116.96. Following the completion of the transaction, the insider now directly owns 32,651 shares of the company’s stock, valued at approximately $622,654.57. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,928 shares of company stock valued at $1,082,317. 25.76% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC acquired a new position in Collegium Pharmaceutical during the second quarter worth about $125,000. Benjamin F. Edwards & Company Inc. raised its stake in Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after acquiring an additional 3,500 shares in the last quarter. Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after acquiring an additional 2,802 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Collegium Pharmaceutical during the fourth quarter worth about $176,000. Finally, JPMorgan Chase & Co. acquired a new position in Collegium Pharmaceutical during the third quarter worth about $192,000. 87.60% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/03/11/50-31-million-in-sales-expected-for-collegium-pharmaceutical-inc-coll-this-quarter.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.